Table 1.

Baseline characteristics of eligible studies in the meta-analyses

Study	Year	Country	Study design	Sample size	Male/ Female ratio	Mean age	Histology (clear cell%)	Survival analysis	Definition of hypertension	Type of analysis	TKIs	Quality Assessment (NOS Score = 9)
Rini (a) [10]	2011	the USA	R	534	2.3	60.6	98%	PFS, OS	SBP ≥ 140 mmHg, DBP ≥ 90 mmHg	multivariate	SUN	7
Szmit [12]	2011	Poland	R	111	3.0	55.9	100%	PFS, OS	BP ≥ 140/90 mmHg	univariate	SUN	9
Bono [17]	2011	Finland	R	64	1.7	64	92%	PFS	BP > 150/100 mmHg OR blood pressure requiring intensifi cation of pre-existing anti-hypertensive medication.	multivariate	SUN	7
Fujita [18]	2012	Japan	R	41	2.7	64	100%	PFS	–	univariate	SUN	7
Eechoute [19]	2012	Netherlands	R	158	1.7	60	87%	PFS, OS	SBP > 140 mmHg, DBP > 90 mmHg, MAP > 110 mmHg	multivariate	SUN	7
Rini (b) [13]	2013	the USA	R	168	2.5	60	–	PFS, OS	DBP ≥90 mmHg	multivariate	AXI	7
Motzer (a) [20]	2013	the USA	P	350	2.8	61	100%	PFS, OS	SBP > 140 mmHg, DBP > 90 mmHg	multivariate	AXI	6
Motzer (b) [20]	2013	the USA	P	336	2.5	61	100%	PFS, OS	SBP > 140 mmHg, DBP > 90 mmHg	multivariate	SOR	6
Hong [21]	2013	China	R	136	2.0	56	93%	OS	Hypertension class III/IV	multivariate	SUN	7
Nakano [22]	2013	Japan	R	36	3.5	65.8	61%	PFS	grade 1–3 (NCI-CTCAE, version 3.0)	multivariate	SOR	7
Fujita [23]	2014	Japan	R	44	2.7	63.5	95%	PFS	–	multivariate	SUN	7
Eto [24]	2014	Japan	R	64	2.2	63	97%	OS	DBP ≥90 mmHg	–	AXI	7
Rini (c) [25]	2015	the USA	P	203	2.0	61.9	–	PFS	DBP change from baseline ≥10/15 mmHg	–	AXI	7
Zhang (a) [26]	2015	China	R	256	2.5	58	79%	OS	–	multivariate	SOR	7
Kucharz [27]	2015	Poland	R	28	2.1	65	–	PFS	office SBP ≥140 and/or DBP ≥90 mmHg; home SBP ≥135 and/or DPB ≥85 mmHg; pre-existing medication-controlled arterial hypertension and required additional antihypertensive medication during treatment	multivariate	SUN	7
Izzedine [28]	2015	France	R	212	3.4	57.7	86%	PFS, OS	–	multivariate	SUN	8
Donskov [29]	2015	the USA	R	770	2.6	60	98%	PFS	SBP ≥ 140 mmHg	multivariate	SUN	7
Zhang (b) [30]	2016	China	R	134	2.4	59.8	77%	OS	–	multivariate	SOR	7
Goldstein (a) [14]	2016	Australia	R	479	2.2	59.5	–	PFS, OS	MAP change from baseline>10 mmHg	univariate	PAZ	9
Goldstein (b) [14]	2016	Australia	R	506	2.6187	61	–	PFS, OS	SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg	univariate	PAZ	9
Goldstein (c) [14]	2016	Australia	R	475	3.3394	60.9	–	PFS, OS	SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg	univariate	SUN	9
Cecere [31]	2016	Italy	R	38	1.375	61	84.2%	OS	grade ≥ 3 (NCI-CTCAE, version 4.0)	multivariate	PAZ	7
Miyake [32]	2016	Japan	R	50	4.0000	64	80%	PFS	SBP ≥ 140 or DBP ≥ 90 mmHg	multivariate	SUN	7
Fukuda [15]	2016	Japan	R	62	2.4444	66	92%	PFS, OS	–	univariate	SUN	7
Matias [33]	2017	France	P	106	2.3125	54	90%	PFS, OS	grade ≥ 3 (NCI-CTCAE, version 4.0)	univariate	AXI	7

R Retrospective, P Prospective, PFS Progression-free survival, OS Overall survival, SBP Systolic blood pressure, DBP Diastolic blood pressure, MAP ≈ 2/3 DBP + 1/3 SBP; SUN Sunitinib, AXI Axitinib, SOR Sorafenib, PAZ Pazopanib, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events

—: The data were not available in this study